Covid-19 Living Data

Trial NCT04412538
Publication Pu J, Vaccine, 2021
Dates: 15/05/2020 to 30/08/2020
Funding: Public/non profit (National Key R&D Program of China, the Program of Chinese Academy of Medicine Science and the Major science and technology special projects of Yunnan Province)
Conflict of interest:

Methods
	RCT
	Location : Single center / China Follow-up duration (months): 1.41
	• Low dose, Day 0,14 (n=24) • Medium dose, Day 0,14 (n=24) • High dose, Day 0,14 (n=24) • Placebo Day 0,28 (n=24) • Low dose, Day 0,28 (n=24) • Medium dose, Day 0,28 (n=24) • High dose, Day 0,28 (n=24) • Placebo Day 0,28 (n=24)
Inclusion criteria	Healthy adults aged 18 to 59 years (including boundary values), both men and women. Proven legal identity Participants should understand the contents of the informed consent form, the vaccine in this trial, voluntarily sign the informed consent form, and be capable of using thermometers, scales, and filling in diary cards and contact cards as required Participants should be able to communicate well with investigators, understand and comply with the requirements of this trial Axillary temperature ≤37.0 ℃.
Exclusion criteria	Contraindications for vaccination History of allergy to vaccines or drugs Immunization with any vaccine within 1 month History of abnormal clinical manifestations and serious diseases to be excluded, including but not limited to nervous system, cardiovascular system, blood and lymphatic system, immune system, kidney, liver, gastrointestinal tract, respiratory system, metabolism, bones and other system diseases, and a history of malignant tumors Those who developed acute disease within 2 weeks, or had symptoms of fever or upper respiratory tract infection within 7 days Those who have a hereditary bleeding tendency or coagulation dysfunction, or a history of thrombosis or bleeding disorders Those who cannot tolerate venipuncture, or have a history of halo needles or halo blood Surgical removal of spleen or other important organs for any reason Those who have undergone surgery within 3 months before signing the informed consent, or those who plan to perform surgery during the trial or within 3 months after the end of the trial (including cosmetic surgery, dental and oral surgery) Those who donated or lost blood (≥400 mL) in the past 3 months, who received blood transfusion or use of blood products, or who planned blood donation during the trial Receipt of other investigational or unregistered products (drugs, vaccines, biological product or devices) in the past 3 months, or plan to use other investigational or unregistered products during the study Receipt of immunosuppressive therapy within 6 months before signing the informed consent form, such as long-term systemic glucocorticoid therapy (with systemic glucocorticoid therapy for more than 2 weeks within 6 months, such as prednisone or similar drugs) ), but local administration (such as ointment, eye drops, inhalation, or nasal spray) is allowed. The local administration should not exceed the dosage recommended in the instructions or have any signs of systemic exposure Those who have took soft drugs (such as marijuana) within 3 months before signing the informed consent form or took hard drugs (such as: cocaine, phencyclidine, etc.) within 1 year before the trial Those who smoked more than 5 cigarettes per day within 3 months before signing the informed consent form The weekly drinking volume is greater than 14 units within 3 months before signing the informed consent form (1 unit alcohol approximately equal to 360 mL beer or 45 mL spirits with 40% alcohol content or 150 mL wine) The comprehensive physical examination does not meet the health standards, mainly including: (1) Those with abnormal vital signs with clinical significance. (2) BMI<18 kg/m^2 or> 30 kg/m^2. (3) Abnormal laboratory examination with clinical significance. (4) Those who tested positive for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen, hepatitis B e antigen, hepatitis C virus antibody, or Treponema pallidum antibody (tp-trust) Participants who have a positive pregnancy test, or are breastfeeding, or plan to become pregnant, or plan to donate sperm or eggs from the screening to 12 months after the second vaccination Positive in drug abuse screening during the screening period (Morphine, Methamphetamine, Ketamine, MDMA and Tetrahydrocannabinolic acid) Positive in alcohol breath test during the screening period Positive in SARS-CoV-2 nucleic acid screening or antibodies (IgG or IgM) screening History of severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS) or other coronavirus infection (HCoV-229E, HCoV-OC43, HCoV-NL63, HCoV-HKU1) History of contact with confirmed or suspected cases infected with SARS-CoV-2 within 1 month Any other situations judged by investigators as not suitable for participating in this study.
Interventions
	Intervention 2 IM doses of 50EU, 14 days apart 2 IM doses of 100EU, 14 days apart 2 IM doses of 150EU, 14 days apart 2 IM doses of 50EU, 28 days apart 2 IM doses of 100EU, 28 days apart 2 IM doses of 150EU, 28 days apart
	Control 2 IM doses, 14 days apart2 IM doses, 28 days apart
Participants
	Randomized 192 participants
	Characteristics of participants Type of participants: Healthy volunteers N=192 86 males Children: 0 Pregnant women: 0 Immunocompromized patients: 0 Mean age: 36.7 Age range: NR
	Description of participants Healthy adults aged 18 to 59 years, SARS-CoV-2 nucleic acid or antibodies negative in a single centre in China
Primary outcome
	In the register Adverse reactions/events rate [Time Frame: 7 days after vaccination], Adverse reactions/events rate [Time Frame: 28 days after vaccination]
	In the report Total rate of adverse reactions from 0 to 28 days postimmunization
Documents available	Protocol NR Statistical plan * Data-sharing stated: Yes Data accessibility: NR
Risk of bias Overall The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review	Some concerns
General comment	In addition to the published report, the study registry was used in data extraction and risk of bias assessment. Neither study protocol not statistical analysis plan was available. The reported study is Phase I of a Phase I/II trials. The study achieved its proposed Phase I sample size; Phase II was ongoing at time of data extraction. There were no substantive differences between the trial registry and pre-print report in interventions or outcomes. This trial was updated on May 10th, 2021 after the publication of the study report.